Personalis, Inc. (PSNL)
Stock Price:
$14.21 USD
0.57 (4.18%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
450.61M |
| Revenue (ttm) |
70.29M |
| Net Income (ttm) |
-28.54M |
| Shares Out |
31.71M |
| EPS (ttm) |
-2.00 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$14.21 |
| Previous Close |
$13.64 |
| Change ($) |
0.57 |
| Change (%) |
4.18% |
| Day's Open |
13.81 |
| Day's Range |
13.52 - 14.57 |
| Day's Volume |
263,532 |
| 52-Week Range |
4.27 - 25.64 |
More Stats
| Market Cap |
450.61M |
| Enterprise Value |
330.57M |
| Earnings Date (est) |
Aug 18, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
31.71M |
| Float |
16.37M |
| EPS (basic) |
-1.44 |
| EPS (diluted) |
-2.00 |
| FCF / Share |
-1.09 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
841,092 |
| Short Ratio |
2.59 |
| Short % of Float |
4.32% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
6.41 |
| PB Ratio |
4.41 |
| Revenue |
70.29M |
| Operating Income |
-26.61M |
| Net Income |
-28.54M |
| Free Cash Flow |
-34.28M |
| Net Cash |
120.03M |
| Net Cash / Share |
3.79 |
| Gross Margin |
31.41% |
| Operating Margin |
-37.86% |
| Profit Margin |
-40.60% |
| FCF Margin |
-48.76% |
| ROA |
-15.88% |
| ROE |
-73.10% |
| ROIC |
-90.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
3 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$17.67*
(24.35% upside)
Low
14.0
Current: 14.21
High
24.0
Target: 17.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 65.21 | 37.77 | 9.39 |
| Revenue Growth | 72.62% | 302.15% | - |
| Gross Profit | 22.08 | 11.81 | -2.34 |
| Operating Income | -22.42 | -13.77 | -22.16 |
| Net Income | -25.08 | -19.89 | -23.60 |
| Shares Outstanding | 18.01 | 3.06 | 3.03 |
| Earnings Per Share | -1.39 | -6.49 | -7.78 |
| Operating Cash Flow | -18.07 | 5.57 | 0.29 |
| Capital Expenditures | -8.38 | -7.85 | -5.16 |
| Free Cash Flow | -26.45 | -2.28 | -4.87 |
| Cash & Equivalents | 128 | 19.74 | 22.62 |
| Total Debt | - | 5.00 | 17.51 |
| Net Cash / Debt | 128 | 14.75 | 5.11 |
| Assets | 157 | 41.67 | 33.56 |
| Liabilities | 50.60 | 58.65 | 50.17 |
| Book Value | 107 | -106 | -92.60 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Personalis, Inc. |
| Country |
United States |
| Employees |
181 |
| CEO |
John S. West |
Stock Information
| Ticker Symbol |
PSNL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: PSNL |
Description
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. Personalis, Inc. has partnership with Berry Genomics. The company was founded in 2011 and is headquartered in Menlo Park, California.